ArticleFrontiers in neuroscience2018
The Argus-II Retinal Prosthesis Implantation; From the Global to Local Successful Experience.
Article in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Spatial variation of evoked potentials in porcine retinas characterized by multi electrode array upon stimulation via 3D pyrolytic carbon electrodes.Frontiers in neuroscience · 2026Article
- Visual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans.Brain sciences · 2025Review
- Reliability and stability of Bioelectronic Medicine: a critical and pedagogical perspective.Bioelectronic medicine · 2025Review
- Bioelectronic Therapeutics: A Revolutionary Medical Practice in Health Care.Bioelectricity · 2025Review
- Zeaxanthin dipalmitate-enriched wolfberry extract improves vision in a mouse model of photoreceptor degeneration.PloS one · 2024Article
- Artificial Vision: The High-Frequency Electrical Stimulation of the Blind Mouse Retina Decay Spike Generation and Electrogenically Clamped Intracellular CaBioengineering (Basel, Switzerland) · 2023Article
- Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management.Chemical reviews · 2023Review
- Integrated High-Temporal-Resolution and High-Density Subretinal Prosthesis Using a Correlated Double-Sampling Technique.Sensors (Basel, Switzerland) · 2023Article
- Gene-agnostic approaches to treating inherited retinal degenerations.Frontiers in cell and developmental biology · 2023Review
- Clinical Progress and Optimization of Information Processing in Artificial Visual Prostheses.Sensors (Basel, Switzerland) · 2022Review
- Increased H3K27 trimethylation contributes to cone survival in a mouse model of cone dystrophy.Cellular and molecular life sciences : CMLS · 2022Article
- Carbohydrate based biomaterials for neural interface applications.Journal of materials chemistry. B · 2022Review
- Ultrasound stimulation for non-invasive visual prostheses.Frontiers in cellular neuroscience · 2022Review
- Correlated Activity in the Degenerate Retina Inhibits Focal Response to Electrical Stimulation.Frontiers in cellular neuroscience · 2022Article
- The First Epiretinal Implant for Hereditary Blindness in the Asia-Pacific Region.Hawai'i journal of health & social welfare · 2021Article
- Optogenetics-Mediated Gene Therapy for Retinal Diseases.Advances in experimental medicine and biology · 2021Review
- Energy-Efficient Integrated Circuit Solutions Toward Miniaturized Closed-Loop Neural Interface Systems.Frontiers in neuroscience · 2021Review
- Effect of the electrode array-retina gap distance on visual function in patients with the Argus II retinal prosthesis.BMC ophthalmology · 2020Article
- Optoelectronic Devices for Vision Restoration.Current ophthalmology reports · 2020Article
- Tapping Into the Language of Touch: Using Non-invasive Stimulation to Specify Tactile Afferent Firing Patterns.Frontiers in neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few years, visual prostheses (namely, Argus II retinal implant) and gene therapy have obtained FDA approval in treating blindness resulting from retinitis pigmentosa. Compared to gene therapy; Argus II is less costly with a demonstrated favorable outcome, though the vision is yet artificial. To obtain better results, expectation counseling and preoperative retinal assessment are critical. The global experience with Argus II has enrolled no more than 300 cases so far. The first Argus II retinal prosthesis in Iran was successfully implanted in Shiraz (October 2017). To date, Argus II artificial retina is implanted in four patients in Iran. Beside successful surgery and post-operative care, rehabilitation efforts with validated outcome measures including visual rehabilitation together with neurovisual, visuo-constructive and cognitive rehabilitation/empowerment approaches are expected to boost the functional outcome. A multidisciplinary approach within a cross-functional team would optimize strategies toward better patient outcomes. As such, establishing a collaborative network will foster organized research efforts to better define outcome assessment and rehabilitation strategies. This technology report paper has been an attempt to provide an overview of Argus-II retinal implant global experience as well as the clinical outcome of the so far cases in Iran. Insights from this report were communicated during the first "Brain Engineering and Computational Neuroscience Conference," 31 January-2 February 2018 in Tehran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.